- English (USA)
- English (UK)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Uniqure NV (QURE)
NASDAQ
Currency in USD
Disclaimer
5.650
+1.090(+23.90%)
Closed
After Hours
5.690+0.040(+0.708%)
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
4.820
5.720
52 wk Range
3.730
11.350
QURE Scorecard
Full Analysis
Analysts anticipate sales growth in the current year
Uniqure NV stock price live, this page displays NASDAQ QURE stock exchange data. View the QURE premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Uniqure NV real time stock price chart below.
What Is the Uniqure NV Stock Price Today?
The Uniqure NV stock price today is 5.650.
What Is the Stock Symbol for Uniqure NV?
The stock symbol for Uniqure NV is "QURE."
What Stock Exchange Does Uniqure NV Trade On?
Uniqure NV is listed and trades on the NASDAQ stock exchange.
Is Uniqure NV a Good Stock to Buy?
Determining whether Uniqure NV—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the QURE quote. (ISIN: NL0010696654)
What Is the Uniqure NV Stock Price Today?
The Uniqure NV stock price today is 5.650.
What Is the Stock Symbol for Uniqure NV?
The stock symbol for Uniqure NV is "QURE."
What Stock Exchange Does Uniqure NV Trade On?
Uniqure NV is listed and trades on the NASDAQ stock exchange.
Is Uniqure NV a Good Stock to Buy?
Determining whether Uniqure NV—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the QURE quote. (ISIN: NL0010696654)
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
4.8205.720
52 wk Range
3.73011.350
UnlockQURE Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceFair Price
Upside
Technical Analysis
Neutral
Price Target
17.755
Upside
+214.248%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
6 analysts have revised their earnings upwards for the upcoming period
- Uniqure Nv receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- Uniqure Nv receives Investment Bank Analyst Rating Update
- Investing.com
Pro
Uniqure NV Company Profile
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington’s disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer’s disease; and AMT-210 that is in preclinical trial to treat Parkinson’s disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
Compare QURE to Peers and Sector
Metrics to compare | QURE | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipQUREPeersSector | |
|---|---|---|---|---|
P/E Ratio | −1.0x | −2.3x | −0.6x | |
PEG Ratio | 0.02 | −0.01 | 0.00 | |
Price/Book | 2.8x | 1.6x | 2.6x | |
Price / LTM Sales | 9.9x | 10.5x | 3.2x | |
Upside (Analyst Target) | 263.6% | 264.2% | 44.4% | |
Fair Value Upside | Unlock | 24.4% | 6.2% | Unlock |
FAQ
What Is the Uniqure NV (QURE) Stock Price Today?
The Uniqure NV stock price today is 5.65.
What Stock Exchange Does Uniqure NV Trade On?
Uniqure NV is listed and trades on the NASDAQ stock exchange.
What Is the Stock Symbol for Uniqure NV?
The stock symbol for Uniqure NV is "QURE."
What Is the Uniqure NV Market Cap?
As of today, Uniqure NV market cap is 275.14M.
What is Uniqure NV Earnings Per Share?
The Uniqure NV EPS is -5.91.
What Is the Next Uniqure NV Earnings Date?
Uniqure NV will release its next earnings report on 28 Oct 2024.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.